Effect of Curcumin on Interleukin-6 Expression and Malondialdehyde Levels in Liver Fibrosis
DOI:
https://doi.org/10.3889/oamjms.2022.10694Keywords:
Curcumin, Liver fibrosis, Common bile duct ligation, IL-6, MDAAbstract
BACKGROUND: Chronic inflammation and excessive oxidative stress are the main mechanisms causing liver fibrosis. It releases anti-inflammatory cytokines, namely, interleukin 6 (IL-6), nitric oxide, and malondialdehyde (MDA). Curcumin acts as an anti-inflammatory, antioxidant, and antifibrotic.
AIM: This study is aimed to analyze differences in IL-6 expression and MDA levels in (Deutschland, Denken, and Yoken) DDY mice with liver fibrosis after common bile duct ligation between the curcumin-treated and control groups.
METHODS: This research is an experimental study with a post-test-only control group design. Seventy-five male DDY mice 20–30g were used in this study (n = 5). Mice were randomly divided into five groups, each consisting of 15 mice. The first group healthy control (HC) was the HC group given phosphate-buffered saline (PBS) solution and did not perform the CBDL. The second group negative control (NC) was a NC group given PBS solution and completed the CBDL. The third group positive control (PC) was a PC group given oral ursodeoxycholic acid (UDCA) and performed CBDL. The fourth group (P1) was assigned oral curcumin and performed the CBDL. The fifth group (P2) was given oral curcumin and UDCA and performed the CBDL. Seven, fourteen, and 21 days after ligation, liver samples were taken to examine IL-6 expression and MDA levels.
RESULTS: There was a significant difference between the NC and PC groups (p = 0.00), NC and P1 (p = 0.00), NC with P2 (p = 0.00), PC with P1 (p = 0.04), PC with P2 (p = 0.04), on day 21 between the NC and PC groups (p = 0.00), NC with P1 (p = 0.00), and PC with P2 (p = 0.00). Statistical analysis of the comparison of MDA levels on days 7 and 14 found no significant difference. On day 21, there was a substantial difference between the NC group and P1 (p = 0.02).
CONCLUSION: This study concluded that curcumin effectively reduced IL-6 expression and MDA levels in liver fibrosis.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Anom ST, Wibawa I. Diagnosis approach and liver fibrosis therapy. J Intern Med. 2012;11(1):57-67.
Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (fibrotest). BMC Gastroenterol. 2010;10:40. https://doi.org/10.1186/1471-230X-10-40 PMid:20412588 DOI: https://doi.org/10.1186/1471-230X-10-40
Hammerich L, Tacke F. Interleukins in chronic liver disease: Lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014;7:297-306. https://doi.org/10.2147/CEG.S43737 PMid:25214799 DOI: https://doi.org/10.2147/CEG.S43737
Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16(11):26087-124. https://doi.org/10.3390/ijms161125942 PMid:26540040 DOI: https://doi.org/10.3390/ijms161125942
Portmann B, Nakanuma Y. Diseases of the bile ducts. In: Pathology of the Liver. 7th ed. London: Churchill Livingstone; 2002. p. 435-506.
Rina RM, Oswari H, Amalia P. Ursodeoxycholic acid in neonatal sepsis-associated cholestasis. Paediatr Indones. 2014;54(4):206-12. https://doi.org/10.14238/pi54.4.2014.206-12 DOI: https://doi.org/10.14238/pi54.4.2014.206-12
Ali MH, Messiha BA, Abdel-Latif HA. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol. 2016;54(7):1198-208. https://doi.org/10.3109/13880209.2015.1060247 PMid:26134756 DOI: https://doi.org/10.3109/13880209.2015.1060247
Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001;35(1):134-46. https://doi.org/10.1016/s0168-8278(01)00092-7 PMid:11495032 DOI: https://doi.org/10.1016/S0168-8278(01)00092-7
Elgaml SA, Hashish EA. Clinicopathological studies of thymus vulgaris extract against cadmium induced hepatotoxicity in Albino rats. Glob J Pharmacol. 2014;8(4):501-9. https://doi.org/10.5829/idosi.gjp.2014.8.4.8444
Friedman S, Arthur MJ. Reversing hepatic fibrosis. Sci Med. 2002;8(4):194-205.
Alizadeh M, Kheirouri S. Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: A comprehensive meta-analysis of randomized controlled trials. Biomedicine (Taipei). 2019;9(4):23. https://doi.org/10.1051/bmdcn/2019090423 PMid:31724938 DOI: https://doi.org/10.1051/bmdcn/2019090423
Azam E, Ameneh K. Curcumin attenuates hepatic fibrosis and insulin resistance induced by bile duct ligation in rats. Br J Nutr. 2018;120(4):393-403. https://doi.org/10.1017/S0007114518001095 PMID: 29880071 DOI: https://doi.org/10.1017/S0007114518001095
Ko WK, Lee SH, Kim SJ, Jo MJ, Kumar H, Han IB, et al. Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PLoS One. 2017;12(6):e0180673. https://doi.org/10.1371/journal.pone.0180673 PMid:28665991 DOI: https://doi.org/10.1371/journal.pone.0180673
Nevzorova YA, Tolba R, Trautwein C, Liedtke C. Partial hepatectomy in mice. Lab Anim. 2015;49(1 Suppl):81-8. https://doi.org/10.1177/0023677215572000 PMid:25835741 DOI: https://doi.org/10.1177/0023677215572000
Farashbandi AL, Shariati M, Mokhtari M. Comparing the protective effects of curcumin and ursodeoxycholic acid after ethanol-induced hepatotoxicity in rat liver. Ethiop J Health Sci. 2021;31(3):673-82. https://doi.org/10.4314/ejhs.v31i3.25 PMid:34483625
Gheibi S, Ghaleh HE, Motlagh BM, Azarbayjani AF, Zarei L. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. Biomed Pharmacother. 2019;115:108938. https://doi.org/10.1016/j.biopha.2019.108938 PMid:31071511 DOI: https://doi.org/10.1016/j.biopha.2019.108938
Shimizu I, Shimamoto N, Saiki K, Furujo M, Osawa K. Lipid peroxidation in hepatic fibrosis. In: Catala A, editor. Lipid Peroxidation. Rijeka: IntechOpen; 2012. DOI: https://doi.org/10.5772/46180
Jeyabalan A, Caritis SN. Antioxidants and the prevention of preeclampsia--unresolved issues. N Engl J Med. 2006;354(17):1841-3. https://doi.org/10.1056/NEJMe068046 PMid:16641402 DOI: https://doi.org/10.1056/NEJMe068046
Razori MV, Maidagan PM, Ciriaci N, Andermatten RB, Barosso IR, Martín PL, et al. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis. Biochem Pharmacol. 2019;168:48-56. https://doi.org/10.1016/j.bcp.2019.06.009 PMid:31202734 DOI: https://doi.org/10.1016/j.bcp.2019.06.009
Li W, Jiang L, Lu X, Liu X, Ling M. Curcumin protects radiation-induced liver damage in rats through the NF-κB signaling pathway. BMC Complement Med Ther. 2021;21(1):10. https://doi.org/10.1186/s12906-020-03182-1 PMid:33407412 DOI: https://doi.org/10.1186/s12906-020-03182-1
Salman M, Randa, Rahman A. Patho-physiological studies on the reverse effect of Curcumin (Curcuma longa, Zingiberaceae) and ursofalk (ursodeoxycholic acid) against the toxicity of carbon tetrachloride on albino rats. J Liver. 2016;5(3):4-6. https://doi.org/10.4172/2167-0889.1000200 DOI: https://doi.org/10.4172/2167-0889.1000200
Suliman AH, Bahjat AA, Abdullah SS, Abbas OE, Mohammad D, Samaa SK, et al. Suppression of hepatic apoptosis induced by acetaminophen using a combination of resveratrol and quercetin: An association of oxidative and interleukin-11. Int J Morphol. 2020;38(1):83-90. DOI: https://doi.org/10.4067/S0717-95022020000100083
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Natasha Aurellia, Neni Susilaningsih, Erik Prabowo, Muflihatul Muniroh, Bernadus Parish Budiono (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
